PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
All content for PeerVoice Oncology & Haematology Audio is the property of PeerVoice and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?
PeerVoice Oncology & Haematology Audio
55 minutes 23 seconds
11 months ago
Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?
Visit https://www.peervoice.com/DFF860 to view the entire programme with slides. After completing “Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?”, participants will be able to: Explain the key characteristics of an oncolytic immunotherapy for advanced melanoma; Discuss the rationale for combining an oncolytic immunotherapy and a systemic immunotherapy in patients with melanoma who have progressed on an anti-PD1 therapeutic regimen; Evaluate the latest clinical data for oncolytic immunotherapy in combination with a systemic immunotherapy in patients with advanced melanoma who have progressed on an anti-PD1 therapy; and Use patients and disease characteristics to identify patient eligibility and suitability for oncolytic immunotherapy in combination with a systemic immunotherapy in patients with advanced melanoma.
PeerVoice Oncology & Haematology Audio
PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
